It's not the technology of gene therapy but the regulation of clinical trials that we should be most afraid of, says Apoorva Mandavilli.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Bekelman, J. E. et al. J. Am. Med. Assoc. 289, 454-465 (2003).
Rights and permissions
About this article
Cite this article
Mandavilli, A. Risky business. Nature (2007). https://doi.org/10.1038/news070820-1
Published:
DOI: https://doi.org/10.1038/news070820-1
